Frontiers in Clinical Drug Research – Diabetes and Obesity is an eBook series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the eBook series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research. The second volume of this series features 7 reviews presenting updates on hormones and several classes of drugs: -Osteocalcin action in glucose metabolism -Sodium-glucose co-transporter 2 (SGLT2) inhibitors -Glucagon-like peptide-1 (GLP-1) mimetics -Dipeptidyl peptidase 4 (DPP-4) inhibitors -New drugs in clinical trial and commercial phases

"Frontiers in Clinical Drug Research – Diabetes and Obesity is an eBook series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the eBook series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research. The third volume of this series features 5 chapters that cover a variety of topics including: -Exendin-4 and its derivatives -The growth hormone/insulin-like growth factor system -Insulin and cardiovascular function -Diabetes mellitus related infertility -Adipocytokines as markers of insulin resistance "

Frontiers in Clinical Drug Research – Diabetes and Obesity is an eBook series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the eBook series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research.</p> <p> The fourth volume of this series features 7 chapters: </p> <p> -Pharmacologic Obesity Treatment </p> <p> -Interplay Between Bile Acid and GLP-1 Receptor Agonist Signaling Informs the Design of Drugs to Combat Obesity and its Metabolic Complications </p> <p> -Sodium–Glucose Co-Transporters Inhibitors for Type 2 Diabetes Mellitus </p> <p> -The Effects of Traditional Chinese Medicine on Inflammatory Cytokines in Diabetic Nephropathy </p> <p> -Through the Perspective of Histology – The Alzheimer’s Disease Promotion by Obesity and Glucose Metabolism: Type 3 Diabetes </p> <p> -Pharmacological Mechanism of PPARγ Ratio in Diabetes and Obesity </p> <p> -Hydrogen Sulfide and Carbohydrate Metabolism </p>

Frontiers in Clinical Drug Research – Diabetes and Obesity is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research. The fifth volume of this series features 5 reviews which are informative guides to therapy and drug administration in diabetes and metabolic syndrome, for both the medical specialist and the pharmacologist. -Metabolic syndrome in schizophrenia -Insulin therapy and foetoplacental endothelial dysfunction in gestational diabetes mellitus -Insights on diabetes, oxidative stress and antioxidant therapeutic strategies -Administration of nano drugs in the treatment of diabetes mellitus -SGLT-2 inhibitors

Frontiers in Clinical Drug Research – Diabetes and Obesity is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases – diabetes and obesity. The scope of the series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research – Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research. The sixth volume of this series features 6 reviews which are informative guides to therapy and drug administration in diabetes and metabolic syndrome, for both the medical specialist and the pharmacologist. - The failing heart in diabetes with special emphasis on prevention - Flavonoids as prominent anti-diabetic agents - Chemosensor in glucose monitoring, advances and challenges - Synergistic drugs and polyherbal formulations for obesity: current status and future prospectives - Urge for herbal anti-diabetic medicines towards clinical and therapeutic implications - Curcuma longa as dietary supplement and diabetes mellitus: evidence from experimental studies

Frontiers in Clinical Drug Research &ndash; Diabetes and Obesity is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of two metabolic diseases &ndash; diabetes and obesity. The scope of the series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs affecting endocrine and metabolic processes linked with diabetes and obesity. Reviews in this series also include research on specific receptor targets and pre-clinical / clinical findings on novel pharmaceutical agents. Frontiers in Clinical Drug Research &ndash; Diabetes and Obesity is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of diabetes and obesity research. The seventh volume of this series features 6 reviews on diabetes related topics for both medical specialists and pharmacologists. - Clinical and diagnostic implications of glycated albumin in diabetes mellitus. - Development of novel therapeutic groups and bioactive compounds from herbs for diabetes management - Aspartame as a sugar substitute - Mental health, adherence, and self-management among children with diabetes - Cardioprotective effects of new generation anti-diabetic and lipid-lowering agents - Epidemiology, pathophysiology, and treatment of diabesity

Hypercalcemia is a relatively common disorder, which requires specific treatment in order to control symptoms and prevent the development of organ damage. Primary hyperparathyroidism and malignancy are responsible for most cases of hypercalcemia, and treatment has therefore been focused towards these two areas. The aim of this book is to present updated knowledge on hypercalcemia, its association with renal disorders, and benign and malignant diseases, diagnostic methodologies, as well as surgical and medical treatment. Insights into the etiology, pathogenesis and pathophysiology of hypercalcemia are included along with details on biochemical findings and ways to monitor complications and therapy. Suggestions on current imaging techniques and surgical treatment of hypercalcemia, are also presented. The book presents an overview on the pharmacology of anti-hypercalcemic drugs, also providing information on new drugs and future perspectives. The book will serve as a comprehensive reference source for oncologists, nephrologists, endocrinologists, clinicians, biochemists and pharmacologists, as well those involved in hypercalcemia management and research.

Insulin resistance is the main factor involved in the occurrence of the metabolic syndrome and later development of type2 diabetes. Despite decades of research on hormone's target tissues and the identification of most diverse candidates, the factors responsible for insulin resistance are still largely undefined. There is also a large discrepancy between in vitro and in vivo insulin sensitivity. Finally it is increasingly demonstrated that insulin resistance is found very early in life, long before metabolic syndrome is established. In search for commonalities, this book deals therefore with a new hypothesis considering microcirculation as one prime, possibly causal effector of insulin resistance. To present this novel hypothesis, the specificities of microvascular physiological mechanisms and the limits of interpretations of data according to the measurement techniques used are first thoroughly described. Several chapters deal with experimental and clinical investigations showing the involvement of microcirculation in insulin resistance. This book provides sound support for microcirculation being linked to insulin resistance at least in a bidirectional way. Supportive evidence suggests that microvascular dysfunction may lie upstream of insulin resistance in many of them. While this is still a hypothesis, the authors believe that there is enough data supporting it and hope that this book will stimulate researchers to provide the necessary final proofs.

The renin-angiotensin system (RAS) is a hormonal system that is responsible for regulating plasma sodium ion concentration and arterial blood pressure in the body. The system involves several peptides such as angiotensin I and II as well as angiotensin converting enzyme (ACE) to enable the constriction of arterial blood vessels in the lung. Angiotensin II also stimulates the production of the hormone aldosterone in the kidneys which brings sodium ions into the bloodstream in exchange for potassium ions. Malfunctions of the RAS can lead to hypertension, heart failure, diabetes and renal complications. Thus the biochemical components of this system serve as important targets for therapeutic drugs. This monograph is a compilation of updated reviews on the RAS. The monograph covers describes the components of the system to explaining its physiological and clinical features in the cardiovascular system and the kidneys. This is followed by sections explaining the biochemistry of the RAS system in cardiovascular and renal disease and the pharmacology of relevant therapeutic drugs. Additional information on the effect of exercise states and methods to quantify angiotensins for molecular diagnosis is also presented in the concluding sections. Information in the monograph will be of interest to physiologists and endocrinologists involved in medical studies or clinical practice. Readers will be able to understand the RAS with a holistic frame of reference.

Phytotherapy in the Management of Diabetes and Hypertension is a good addition to existing volumes detailing knowledge of hyperglycemia therapy. This e-book emphasizes the basic biochemistry behind diabetes mellitus and hypertension, along with the control or remediation of these conditions through a cost effective, safe, easy-going, easy-adaptable method validated by scientific research. This e-book contains 7 chapters dealing with various aspects of these diseases and their Phytotherapy treatment and life style management. Phytotherapy can give patients long term benefits with less or no side effects. Hence, this e-book is an authentic alternative or complementary therapeutic compendium to physicians and patients. This book will also be useful to students, teachers, researchers, clinicians and general readers interested in learning about applied phytotherapy.